University Medical Center Freiburg Trials

University Medical Center Freiburg	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Samii, Ali

CT-AMT-130-01, NCT04120493: Safety and Proof-of-Concept (POC) Study with AMT-130 in Adults with Early Manifest Huntington's Disease

	Jan 2021 - Dec 2021 : Early efficacy data on initial patients for Huntington's disease
	First biomarker data from trial for Huntington’s disease
	Nov 2021 - Nov 2021: First biomarker data from trial for Huntington’s disease
	Safety data from P1/2 trial for Huntington’s disease
	Feb 2021 - Feb 2021: Safety data from P1/2 trial for Huntington’s disease

Recruiting

1/2

intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery

UniQure Biopharma B.V.

Huntington's Disease

04/29

06/29

NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting

N/A

35000

Europe, Canada, US, RoW

CHDI Foundation, Inc.

Huntington's Disease

01/62

Hasenburg, Annette

COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Completed

Europe

Trabectidin (Yondelis)

North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar

Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma

08/23

Schmidt, Stefan M

ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Active, not recruiting

117

Europe, RoW

Ropeginterferon alfa-2b (BESREMi®)

AOP Orphan Pharmaceuticals AG

Essential Thrombocythaemia

03/28

Grosu, Anca-Ligia

HypoF-SBRT, NCT06330909: Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt

Recruiting

N/A

374

Europe

Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT, Intensity modulated radiotherapy (IMRT), Image guided radiotherapy (IGRT), Stereotactic Body Radiation Therapy (SBRT), Radiotherapy (RT) Arm B - IMRT/IGRT

University Hospital Freiburg, German Federal Ministry of Education and Research

Prostate Cancer

08/25

02/30

TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting

N/A

982

Europe, Canada, Japan, US, RoW

Optune®

NovoCure Ltd.

Glioblastoma Multiforme

01/26

DELPHI, NCT03396718: De-escalation of Adjuvant Radio (chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

Recruiting

N/A

304

Europe

De-escalation radio(chemo)therapy - Level 1, De-escalation radio(chemo)therapy - Level 2, Standard radio(chemotherapy)

Technische Universität Dresden, German Cancer Research Center, National Center for Tumor Diseases (NCT) Dresden, National Center for Tumor Diseases, Heidelberg, Radiation Oncology Working Group of the German Cancer Society

Head-and-neck Squamous Cell Carcinoma

11/29

11/32

Bettinger, Dominik

CVID-pHT, NCT06145100: Prediction of Portal Hypertension in Patients With CVID

Recruiting

N/A

250

Europe

Ultrasound including color doppler ultrasound, Liver stiffness measurement by transient elastography, Spleen stiffness measurement by transient elastography

University Hospital Freiburg

Non-Cirrhotic Portal Hypertension, Common Variable Immunodeficiency

12/25

Terli-CKD, NCT06161766: Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

Completed

N/A

490

Europe

terlipressin or noradrenalin plus albumin

University Hospital Freiburg, Jena University Hospital, Johannes Gutenberg University Mainz, University Hospital Muenster

Liver Cirrhosis, Hepato-Renal Syndrome, Chronic Kidney Diseases

12/24

Liver-HERO, NCT05346393: HRS-AKI Treatment With TIPS in Patients With Cirrhosis

Recruiting

N/A

124

Europe

TIPS, Standard of Care, Terlipressin + Albumin

Jena University Hospital, German Research Foundation, University Hospital Halle (Saale)

Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic

06/25

06/26

NCT05949268: Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel

Recruiting

N/A

1300

Europe

Small bowel capsule endoscopy

University Hospital Freiburg

GastroIntestinal Bleeding

12/27

07/28

FRETIR, NCT05782556: Freiburg TIPS Registry

Recruiting

N/A

2000

Europe

Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)

University Hospital Freiburg

Liver Cirrhosis, Portal Hypertension, Non-Cirrhotic Portal Hypertension, Budd Chiari Syndrome, Portal Vein Thrombosis, Portal Systemic Shunt

12/33

06/34

NCT05661331: VIATORR Device Registry

Recruiting

N/A

196

Europe

Transjugular intrahepatic portosystemic shunt, TIPS

W.L.Gore & Associates

Chronic Liver Disease

01/25

01/28

SchultheiÃŸ, Michael

FRETIR, NCT05782556: Freiburg TIPS Registry

Recruiting

N/A

2000

Europe

Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)

University Hospital Freiburg

Liver Cirrhosis, Portal Hypertension, Non-Cirrhotic Portal Hypertension, Budd Chiari Syndrome, Portal Vein Thrombosis, Portal Systemic Shunt

12/33

06/34

Engelhardt, Monika

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

MYRIAM, NCT03308474: Myeloma Registry Platform

Recruiting

N/A

2200

Europe

Routine care as per site standard.

iOMEDICO AG, Deutsche Studiengruppe Multiples Myelom (DSMM)

Multiple Myeloma

12/26

12/28

Kirschner, Janbernd

MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)

Active, not recruiting

160

Europe, US, RoW

Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS

Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.

Muscular Dystrophy, Duchenne

10/26

PASTA, NCT04873583 / 2021-005571-39: High Dose Steroids in Children With Stroke

Recruiting

Europe, RoW

Methylprednisolone, Solu-Medrol, Prednisolone, Spiricort

Insel Gruppe AG, University Hospital Bern, University of Bern

Paediatric Stroke

08/25

07/26

ULYSSES, NCT05933057: Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Recruiting

138

Europe, Canada

Givinostat, ITF2357, Placebo

Italfarmaco, Fortrea

Duchenne Muscular Dystrophy

02/28

PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1633

Europe, Japan, US, RoW

Lasmiditan, LY573144, Placebo

Eli Lilly and Company

Migraine

01/25

PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1000

Europe, Japan, US, RoW

Lasmiditan, LY573144

Eli Lilly and Company

Migraine

03/26

SCREEN4CARE, NCT06549218: Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project

Recruiting

N/A

20000

Europe

newborn genetic screening and whole genome sequencing

University Hospital Freiburg, Innovative Medicines Initiative, Università degli Studi di Ferrara, Ospedale Pediatrico Bambin Gesù, University of Siena, Centre Hospitalier Universitaire Dijon, Real Genix, University Hospital Erlangen, University Hospital Goettingen, Centro Nacional de Análisis Genómico, Genoox

Newborn Screening

12/25

Jaeger, Martin

NCT04113044: Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®

Recruiting

N/A

3500

Europe, US, RoW

All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics., Patient Reported Outcomes

AO Innovation Translation Center

Hip Fractures, Tibial Fractures, Ankle Fractures, Humeral Fracture, Proximal, Distal Radius Fracture

12/26

Argarwal, Pinky

NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting

N/A

35000

Europe, Canada, US, RoW

CHDI Foundation, Inc.

Huntington's Disease

01/62

Heeg, Steffen

CABONEN, NCT04524208: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

Active, not recruiting

Europe

Cabozantinib

Karsten Gavenis

Neuroendocrine Tumors, Neuroendocrine Carcinoma

09/24

10/24

Finzel, Stephanie

OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Recruiting

160

Europe, Canada, Japan, US, RoW

Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab

GlaxoSmithKline

Eosinophilic Granulomatosis With Polyangiitis

10/25

11/25

NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis

Active, not recruiting

2/3

301

Europe, Japan, US, RoW

HZN-825 BID, Placebo, HZN-825 QD

Amgen, Horizon Therapeutics USA, Inc

Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic

09/25

PASTOR, NCT04062695 / 2018-004254-22: Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement

Recruiting

Europe

Tofacitinib 5 MG Oral Tablet [Xeljanz], Xeljanz, Placebo oral tablet

Charite University, Berlin, Germany, Pfizer Pharma GmbH, unrestricted grant

Psoriatic Arthritis, Spondylitis, Sacroilitis

12/23

Lupus-Best, NCT05714930: LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

Recruiting

N/A

606

Europe

Treat-to-target as a new treatment concept

Heinrich-Heine University, Duesseldorf, University Hospital Heidelberg, German Diabetes-Center, Leibniz-Institut in Düsseldorf, Lupus Erythematodes-Selbsthilfegemeinschaft e.V.

Systemic Lupus Erythematosus

04/26

09/26

Kammel, Gerit

NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting

N/A

35000

Europe, Canada, US, RoW

CHDI Foundation, Inc.

Huntington's Disease

01/62

Rijntjes, Michel

ADOPTION, NCT04990284 / 2020-002754-24: eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.

Active, not recruiting

106

Europe

Opicapone, BIA 9-1067, L-DOPA/DDCI, Levodopa

Bial - Portela C S.A., Bial - Portela & Ca, S.A.

Parkinson Disease

06/23

NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting

N/A

35000

Europe, Canada, US, RoW

CHDI Foundation, Inc.

Huntington's Disease

01/62

Contract, Central

TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study )

Terminated

1370

Europe, US, RoW

BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo

CSL Behring

Traumatic Injury

10/24

Meffle, Carmen

TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting

N/A

982

Europe, Canada, Japan, US, RoW

Optune®

NovoCure Ltd.

Glioblastoma Multiforme

01/26



	Diseases Companies Products Productz Mechanisms of Action Sites